ARTICLE | Clinical News
Eli Lilly enzastaurin preliminary Phase II data
May 18, 2005 12:01 AM UTC
LLY said a preliminary analysis of a Phase II trail to treat glioblastoma multiforme (GBM) showed that patients given enzastaurin (LY-317615) had a 20-25% response rate. LLY would not comment on wheth...